[go: up one dir, main page]

MA31169B1 - Preparation solide comprenant de l'alogliptine et de la pioglitazone - Google Patents

Preparation solide comprenant de l'alogliptine et de la pioglitazone

Info

Publication number
MA31169B1
MA31169B1 MA32148A MA32148A MA31169B1 MA 31169 B1 MA31169 B1 MA 31169B1 MA 32148 A MA32148 A MA 32148A MA 32148 A MA32148 A MA 32148A MA 31169 B1 MA31169 B1 MA 31169B1
Authority
MA
Morocco
Prior art keywords
pioglitazone
solid preparation
alogliptin
sugar
excipient
Prior art date
Application number
MA32148A
Other languages
Arabic (ar)
English (en)
Inventor
Junya Nomura
Kenji Nakamura
Kenichiro Kiyoshima
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39240362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31169(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA31169B1 publication Critical patent/MA31169B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur une préparation solide contenant un composé (i), dont la définition est donnée dans la description, et de la pioglitazone, qui est utile comme médicament thérapeutique pour le diabète et similaires et présente des propriétés supérieures de dissolution, de stabilité chimique et de stabilité de dissolution. L'invention porte également sur une préparation solide contenant les première et seconde parties suivantes : (1) la première partie contenant le composé (i) ou un sel de celui-ci et, comme premier excipient, du sucre ou un alcool de sucre ; et (2) une seconde partie contenant de la pioglitazone ou un sel de celle-ci et, comme second excipient, du sucre ou un alcool de sucre.
MA32148A 2007-02-01 2009-08-06 Preparation solide comprenant de l'alogliptine et de la pioglitazone MA31169B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007023594 2007-02-01
PCT/JP2008/051900 WO2008093882A1 (fr) 2007-02-01 2008-01-30 Préparation solide comprenant de l'alogliptine et de la pioglitazone

Publications (1)

Publication Number Publication Date
MA31169B1 true MA31169B1 (fr) 2010-02-01

Family

ID=39240362

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32148A MA31169B1 (fr) 2007-02-01 2009-08-06 Preparation solide comprenant de l'alogliptine et de la pioglitazone

Country Status (38)

Country Link
US (1) US8637079B2 (fr)
EP (1) EP2107905B1 (fr)
JP (1) JP5284968B2 (fr)
KR (1) KR101486091B1 (fr)
CN (1) CN101646420B (fr)
AR (1) AR065097A1 (fr)
AT (1) ATE488227T1 (fr)
AU (1) AU2008211981B2 (fr)
BR (1) BRPI0807453B8 (fr)
CA (1) CA2677201C (fr)
CL (1) CL2008000279A1 (fr)
CR (1) CR10992A (fr)
CY (1) CY1111264T1 (fr)
DE (1) DE602008003522D1 (fr)
DK (1) DK2107905T3 (fr)
DO (1) DOP2009000195A (fr)
EA (1) EA015180B1 (fr)
EC (1) ECSP099608A (fr)
ES (1) ES2354397T3 (fr)
GE (1) GEP20125410B (fr)
HR (1) HRP20110094T8 (fr)
IL (1) IL200108A (fr)
JO (1) JO2650B1 (fr)
MA (1) MA31169B1 (fr)
ME (1) ME01239B (fr)
MX (1) MX2009008100A (fr)
MY (1) MY147596A (fr)
NZ (1) NZ579008A (fr)
PE (1) PE20081663A1 (fr)
PL (1) PL2107905T3 (fr)
PT (1) PT2107905E (fr)
RS (1) RS51592B (fr)
SI (1) SI2107905T1 (fr)
TN (1) TN2009000317A1 (fr)
TW (2) TWI453041B (fr)
UA (1) UA95828C2 (fr)
WO (1) WO2008093882A1 (fr)
ZA (1) ZA200905621B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
CN101801351B (zh) * 2007-07-19 2012-12-12 武田药品工业株式会社 包含阿格列汀和盐酸二甲双胍的固体制剂
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
WO2010018217A2 (fr) 2008-08-15 2010-02-18 Boehringer Ingelheim International Gmbh Composés organiques pour la cicatrisation de lésion
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
AR073380A1 (es) 2008-09-25 2010-11-03 Takeda Pharmaceutical Composicion farmaceutica solida. comprimido multicapa
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
AU2010212823B2 (en) 2009-02-13 2016-01-28 Boehringer Ingelheim International Gmbh Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
PT2395983T (pt) 2009-02-13 2020-07-03 Boehringer Ingelheim Int Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dp-iv e opcionalmente um agente antidiabético adicional e suas utilizações
KR20120107080A (ko) * 2009-11-27 2012-09-28 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
WO2011113947A1 (fr) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combinaisons d'agonistes de gpr119 et d'inhibiteurs de dpp-iv, linagliptine, pour le traitement du diabète et d'états apparentés
MX2012012438A (es) * 2010-05-05 2012-11-29 Boehringer Ingelheim Int Formulaciones farmaceuticas que comprenden pioglitazona y linagliptina.
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
KR20220025926A (ko) 2010-06-24 2022-03-03 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
CN103781788B (zh) 2011-07-15 2016-08-17 勃林格殷格翰国际有限公司 经取代的喹唑啉、其制备及其在药物组合物中的用途
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171166A1 (fr) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de sirs et/ou d'une sepsie
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
CN103877054B (zh) * 2012-12-21 2016-05-25 北大方正集团有限公司 一种苯甲酸阿格列汀片剂及其制备方法
CN103156819A (zh) * 2013-03-29 2013-06-19 山东罗欣药业股份有限公司 苯甲酸阿格列汀组合物片剂及其制备方法
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
JP6027710B1 (ja) * 2014-12-25 2016-11-16 田辺三菱製薬株式会社 糖尿病治療用固形製剤
EP3310357A1 (fr) * 2015-06-17 2018-04-25 H e x a l Aktiengesellschaft Formulation d'alogliptine
US11000481B2 (en) 2015-06-26 2021-05-11 Korea United Pharm. Inc. Composite preparation of mosapride and rabeprazole
CN105030719B (zh) * 2015-08-20 2018-07-20 杭州成邦医药科技有限公司 一种含有阿格列汀和吡格列酮的组合物
MX390363B (es) 2016-06-10 2025-03-20 Boehringer Ingelheim Int Combinacion de linagliptina y metformina
KR102485766B1 (ko) 2019-12-11 2023-01-09 한국유나이티드제약 주식회사 생체이용률이 향상된 피오글리타존 함유 약학조성물
CN113925838B (zh) * 2021-11-11 2022-11-11 乐普制药科技有限公司 一种依帕司他与西格列汀或其可药用盐的复方缓释片及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
EP0559702B1 (fr) 1990-11-27 1994-12-28 Byk Gulden Lomberg Chemische Fabrik Gmbh Retardateur d'urapidil
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US6030641A (en) * 1997-06-03 2000-02-29 Uni Colloid Kabushiki Kaisha Sustained release capsule and method for preparing the same
JP2931811B2 (ja) 1997-06-03 1999-08-09 ユニコロイド株式会社 徐放性カプセル
DE19725911A1 (de) 1997-06-13 1998-12-17 Roland Prof Dr Bodmeier Zusammensetzungen, die die Wirkstofffreisetzung verzögern
WO1998056359A2 (fr) 1997-06-13 1998-12-17 Roland Bodmeier Compositions retardant la liberation de principes actifs
AU5652199A (en) 1998-09-18 2000-04-10 Takeda Chemical Industries Ltd. Sustained release oral preparations
JP2000154137A (ja) 1998-09-18 2000-06-06 Takeda Chem Ind Ltd 徐放性経口製剤
WO2000078333A2 (fr) * 1999-06-21 2000-12-28 Eli Lilly And Company Utilisation combinee de thiazolidinediones et de peptide-1 de type glucagone et d'agonistes de ces derniers pour traiter l'instabilite metabolique associee aux diabetes non insulino-dependants.
AR030920A1 (es) 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
DK1741446T3 (da) 2000-01-21 2008-06-02 Novartis Pharma Ag Kombinationer indeholdende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US7078397B2 (en) * 2000-06-19 2006-07-18 Smithkline Beecham Corporation Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
CA2492722A1 (fr) * 2002-07-11 2004-01-22 Takeda Pharmaceutical Company Limited Procede de production d'une preparation recouverte
IN192749B (fr) 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
WO2004067001A1 (fr) * 2003-01-29 2004-08-12 Takeda Pharmaceutical Company Limited Procede pour realiser une preparation enrobee
JP4567340B2 (ja) * 2003-01-29 2010-10-20 武田薬品工業株式会社 被覆製剤の製造方法
JP4361461B2 (ja) * 2003-10-31 2009-11-11 武田薬品工業株式会社 固形製剤
US7700128B2 (en) * 2003-10-31 2010-04-20 Takeda Pharmaceutical Company Limited Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
BR122018014389B1 (pt) 2004-01-20 2023-04-25 Novartis Ag Processo para preparar comprimido farmacêutico por compressão direta
GEP20094679B (en) 2004-03-15 2009-05-10 Takeda Pharmaceuticals Co Dipeptidyl peptidase inhibitors
US20090253752A1 (en) 2004-10-25 2009-10-08 Bryan Burkey Combination of dpp-iv inhibitor, ppar antidiabetic and metmorfin
GT200600218A (es) 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
CN101309689B (zh) 2005-09-14 2012-10-10 武田药品工业株式会社 用于治疗糖尿病的二肽基肽酶抑制剂
TW200745079A (en) 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
BRPI0620718A2 (pt) * 2005-10-28 2011-11-22 Takeda Pharmaceutical agente para a proteção do páncreas, e, uso de uma droga para a redução de glicose
JP5179363B2 (ja) 2005-12-22 2013-04-10 武田薬品工業株式会社 固形製剤

Also Published As

Publication number Publication date
HK1138188A1 (en) 2010-08-20
HRP20110094T1 (hr) 2011-03-31
DOP2009000195A (es) 2009-08-31
PL2107905T3 (pl) 2011-04-29
TWI453041B (zh) 2014-09-21
MX2009008100A (es) 2009-08-07
ES2354397T3 (es) 2011-03-14
GEP20125410B (en) 2012-02-27
JP5284968B2 (ja) 2013-09-11
ECSP099608A (es) 2009-09-29
TW201350143A (zh) 2013-12-16
CA2677201C (fr) 2015-11-17
AU2008211981A1 (en) 2008-08-07
UA95828C2 (ru) 2011-09-12
ME01239B (me) 2013-06-20
CL2008000279A1 (es) 2008-08-18
EP2107905B1 (fr) 2010-11-17
CN101646420B (zh) 2012-11-07
JP2010517937A (ja) 2010-05-27
DK2107905T3 (da) 2011-01-31
EP2107905A1 (fr) 2009-10-14
IL200108A (en) 2012-02-29
PT2107905E (pt) 2010-12-17
MY147596A (en) 2012-12-31
CR10992A (es) 2009-09-16
BRPI0807453B8 (pt) 2021-05-25
ZA200905621B (en) 2010-10-27
RS51592B (sr) 2011-08-31
SI2107905T1 (sl) 2011-03-31
CY1111264T1 (el) 2015-08-05
HRP20110094T8 (en) 2011-07-31
KR20090109115A (ko) 2009-10-19
KR101486091B1 (ko) 2015-01-23
AU2008211981B2 (en) 2012-09-20
PE20081663A1 (es) 2008-12-25
BRPI0807453B1 (pt) 2021-01-05
BRPI0807453A2 (pt) 2014-05-20
EA015180B1 (ru) 2011-06-30
WO2008093882A1 (fr) 2008-08-07
US20100092551A1 (en) 2010-04-15
TN2009000317A1 (en) 2010-12-31
ATE488227T1 (de) 2010-12-15
JO2650B1 (en) 2012-06-17
EA200970726A1 (ru) 2010-02-26
CN101646420A (zh) 2010-02-10
NZ579008A (en) 2012-02-24
TW200836775A (en) 2008-09-16
CA2677201A1 (fr) 2008-08-07
AR065097A1 (es) 2009-05-13
US8637079B2 (en) 2014-01-28
DE602008003522D1 (de) 2010-12-30
IL200108A0 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
MA31169B1 (fr) Preparation solide comprenant de l'alogliptine et de la pioglitazone
Lim et al. Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction
MA30890B1 (fr) Compose indole
MA27058A1 (fr) Cristaux comprenant un sel d'acide malique de n-[2-(diethylamino) ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indole-3-ylidene) methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, procedes pour leur preparation et compositions les contenant
Marriott et al. A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins
MA31592B1 (fr) Preparation solide comprenant l'alogliptine et le chlorhydrate de metformine
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
MA33056B1 (fr) Composition pharmaceutique solide comprenant de l'amlodipine et du losartan et son procede de fabrication
MA32027B1 (fr) Preparation de capsules
WO2004112701A3 (fr) Derives de cyclohexylglycine servant d'inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
TNSN08139A1 (fr) Composes therapeutiques
MA32171B1 (fr) Compose heterocyclique
WO2004069162A3 (fr) Derives d'acide 3-amino-4-phenylbutanoique utilises comme inhibiteurs de dipeptidyle peptidase pour le traitement ou la prevention du diabete
WO2004064778A3 (fr) Derives d'acide 3-amino-4-phenylbutanoique utilises comme inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
MA28673B1 (fr) Derives de pyrazole, compositions contenant lesdits composes et methodes d'utilisation
Thiele et al. Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates
Azam et al. Parasitic diarrheal disease: drug development and targets
TNSN00139A1 (fr) Acides phenoxyacetiques substitues
Nguyen et al. Response: antiapoptotic function of Toso (Faim3) in death receptor signaling
Boesecke et al. Toxicity of HIV protease inhibitors: clinical considerations
Hou et al. LJNK, an indoline-2, 3-dione-based aminopeptidase N inhibitor with promising antitumor potency
Worz et al. The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statins
MA28072A1 (fr) Ecorces de levures pour le traitement ou la prevention de l'hyperglycemie ou pour la stabilisation de la glycemie
DK1888074T3 (da) Middel til forebyggelsen og behandling af leversygdomme indeholdende pyrazolopyrimidinderivat
MA32128B1 (fr) Association entre un sel de bis-thiazolium ou l'un de ses precurseurs et l'artémisinine ou l'un de ses derives pour le traitement du paludisme severe